Aptinyx Inc. (NASDAQ:APTX) will be hosting a conference call at 5:00 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.aptinyx.com
The participants may dial, (833) 772-0394 Toll Free or (236) 738-2205 Toll Number, with passcode : 9186375 in order to access the live audio call
Earnings Expectation
Aptinyx Inc. is reporting third quarter financial results on Thursday 12th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, APTX is expected to report 3Q20 loss of $ 0.29 per share from revenue of $ 0.41 million.
For the full year, analysts anticipate top line of $ 1.86 million, while looking forward to loss of $ 1.22 per share bottom line.
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinsons disease cognitive impairment.
